Table 2.
Results.
| Total | PPV group | Non PPV group | |
|---|---|---|---|
| Preoperative logMAR BCVA | 0.85 ± 0.59 (range 0.05–2.3) |
1.02 ± 0.60 (range 0.05–1.8) |
0.83 ± 0.61 (range 0.15–2.3) |
| 1-month postoperative logMAR BCVA | 0.44 ± 0.30 (range 0.05–1) |
0.65 ± 0.37 (range 0.15–1) |
0.37 ± 0.35 (range 0.05–0.95) |
| 6 months postoperative logMAR BCVA | 0.36 ± 0.34 (range 0.05–1) |
0.47 ± 0.30 (range 0.05–1) |
0.32 ± 0.33 (range 0.05–0.95) |
| 12 months postoperative logMAR BCVA | 0.35 ± 0.32 (range 0.05–1) |
0.50 ± 0.30 (range 0.05–1) |
0.33 ± 0.32 (range 0.05–0.95) |
| 24 months postoperative logMAR BCVA | 0.33 ± 0.32 (range 0.05–0.9) |
0.45 ± 0.27 (range 0.05–0.9) |
0.30 ± 0.31 (range 0.05–0.6) |
| Endothelial cell count | Preoperative | 2472 ± 202 cells/mm2 | 2553 ± 205 cells/mm2 |
| Postoperative | 2387 ± 197 cells/mm2 | 2453 ± 200 cells/mm2 | |
| Indication | Dislocated PC IOL (40.7%) | ||
| AC IOL complication (11.1%) | |||
| Subluxated traumatic cataract (18.5%) | |||
| Subluxated nontraumatic cataract (18.5%) | |||
| Aphakia (11.1%) | |||